
Conference Coverage
about 2 months ago
Cefiderocol Shows Activity Against Difficult-to-Treat Pathogensabout 2 months ago
Does Where People Live Affect Antibiotic Prescribing Practices?2 months ago
Considering Alternatives to Vancomycin for MRSALatest Content

A No-Carb Diet: An Overview of Non–Carbapenemase-Producing Carbapenem-Resistant Enterobacterales

Phase 3 Clinical Trial Reporting, Prospective Regulatory Filings to Watch For in 2026

Invasive Fungal Disease in Transplantation: Prevention in a Shifting Landscape

Prospective Game Changer: Lenacapavir for HIV Preexposure Prophylaxis

COVID-19: The Gaps in Science Communication

Shorts










Podcasts
Videos
Contagion Digital Edition









All News

This week, listen in on commentary around the changes to the childhood vaccine schedule, read SIDP's column on the next-generation antifungals as well as combination therapeutics for Candida auris, and the Clinical and Laboratory Standards Institute Subcommittee on Antimicrobial Susceptibility Testing breakpoint recommendations.

Candida auris is a highly drug-resistant, hospital-acquired fungal pathogen. With limited treatment options, here is an overview of some of the next-generation antifungals as well as combination therapeutics.

The subcommittee approved the removal of doxycycline and tetracycline breakpoints and revised aminoglycoside breakpoints for Acinetobacter spp, and added aztreonam-avibactam breakpoints for Enterobacterales.

Sharon Carrasco DNP, APRN, ACNS-BC, ANP-C, CEN, FAEN, FAAN, FNAP, discusses her approach to training for these care scenarios.

A recent study challenges the need for high-dose trimethoprim-sulfamethoxazole in managing Stenotrophomonas maltophilia pneumonia, finding lower doses may offer comparable efficacy.

A recent study examined how rurality and the availability of post discharge follow-up influence clinicians’ decisions on antibiotic duration at discharge for patients hospitalized with community-acquired pneumonia.

With rates of influenza vaccination in decline, two health systems evaluated interventions for prompting clinicians to order, and patients to obtain flu shots.

Former FDA Chief Scientist Jesse L. Goodman, MD, MPH, provides insights on the potential consequences of these new recommendations.

Sharon Carrasco DNP, APRN, ACNS-BC, ANP-C, CEN, FAEN, FAAN, FNAP, talks about safely responding to deadly pathogens such as Ebola and Lassa fever, and where the US is in terms of thinking about preparedness on a national level.

New federal guidance recommends childhood vaccines for 11 diseases, downsizing immunization protection from the previous list of 18 diseases.

A delay in providing standard infant vaccinations is associated with children not receiving MMR (measles, mumps, rubella) vaccine by 2 years of age.

A series of politically driven actions in 2025—including defunding mRNA research, dismantling vaccine advisory bodies, and restricting CDC recommendations—has undermined US vaccine access and pandemic preparedness, but professional societies and some states are stepping in to preserve evidence-based public health.

This week, read about increasing influenza activity, an approach to de-escalating empiric broad spectrum antibiotics for clinically stable patients with community-onset sepsis, and more Emory Healthcare Media Day interviews around PPE and treating high-consequence infectious disease.

Jill Morgan, RN, BSN, talks about steps being taken to ensure everyone’s safety is front of mind.

CDC surveillance shows sharp week-over-week increases in influenza test positivity, outpatient illness, and hospital admissions, with A(H3N2) continuing to predominate nationwide.















































































































































































































































































































































